Study study type PathologyT1T0Patientssample sizesROB Results

multiple myeloma - 1st line (L1) multiple myeloma - 1st line (L1)

versus lenalidomide and dexamethasone
pembrolizumab plus lenalidomide and dexamethasone
KEYNOTE-185, 2019
  NCT02579863
RCTmultiple myeloma - 1st line (L1)pembrolizumab plus lenalidomide and dexamethasonelenalidomide and dexamethasoneTransplantation-ineligible patients with newly diagnosed active multiple myeloma, who were treatment naive were enrolled,151 / 150some concern
safety concern
  • safety concern with 22 % increase in progression or deaths (PFS) (PE) (not statistically significant)

multiple myeloma - 2nd line (L2) multiple myeloma - 2nd line (L2)

versus pomalidomide and dexamethasone
pembrolizumab plus pomalidomide and dexamethasone
KEYNOTE-183, 2019
  NCT02576977
RCTmultiple myeloma - 2nd line (L2)pembrolizumab plus pomalidomide and dexamethasonepomalidomide and dexamethasonepatients with relapsed or refractory multiple myeloma and at least two previous lines of anti-myeloma therapy,125 / 124some concern
safety concern
  • safety concern with 61 % increase in deaths (OS) (PE) (not statistically significant)
  • safety concern with statistically significant 53 % increase in progression or deaths (PFS) (PE)